Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 1, 2011, Pages 25-33

  Antignac, Marie ^a   Fernandez, Christine ^a,b   Barrou, Benoît ^c   Roca, Mariona ^a   Favrat, Jean Louis ^a   Urien, Saïk ^d   Farinotti, Robert ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b EA4123   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adult patients; Bayesian prediction; Kidney; Population pharmacokinetics; Tacrolimus; Transplantation

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PREDICTION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY;

ADULT; AGED; BAYES THEOREM; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 79954442692     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0027-z     Document Type: Article

References (39)

1. M Antignac B Barrou R Farinotti P Lechat S Urien 2007 Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients Br J Clin Pharmacol 64 6 750 757 17425625 1:CAS:528:DC%2BD1cXhtVKrt7w%3D (Pubitemid 350222052)
2. L Backman M Nicar M Levy D Distant C Eisenstein T Renard R Goldstein B Husberg TA Gonwa G Klintmalm 1994 FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects Transplantation 57 4 519 525 7509516 1:STN:280:DyaK2c7mtVehug%3D%3D (Pubitemid 24075796)
3. Beal SL (1992) Conditional estimation methods. In: california NpgUo (ed) NONMEM users guide. UCSF University of California, San Francisco
4. K Benkali A Premaud N Picard JP Rerolle O Toupance G Hoizey A Turcant F Villemain Y Le Meur P Marquet A Rousseau 2009 Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients Clin Pharmacokinet 48 12 805 816 19902988 10.2165/11318080-000000000-00000 1:CAS:528:DC%2BC3cXmt1Cmtw%3D%3D
5. Box G (1979) Robustness in the strategy of scientific model building. In: Laurer RL, Wilkinson GN (ed) Robustness in statistics. Academic Press, New York, pp 201-236
6. JL Cogill PJ Taylor IS Westley RG Morris SV Lynch AG Johnson 1998 Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients Clin Chem 44 9 1942 1946 9732981 1:CAS:528:DyaK1cXlvVaktbs%3D (Pubitemid 28405760)
7. N Djebli A Rousseau G Hoizey JP Rerolle O Toupance Y Le Meur P Marquet 2006 Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients Clin Pharmacokinet 45 11 1135 1148 17048977 10.2165/00003088-200645110-00007 1:CAS:528:DC%2BD28XhtlWhtbnF (Pubitemid 44631392)
8. EI Ette PJ Williams 2004 Population pharmacokinetics II: estimation methods Ann Pharmacother 38 11 1907 1915 15367729 10.1345/aph.1E259 1:CAS:528:DC%2BD2cXhtVWktrvL (Pubitemid 39425727)
9. FDA USFaDA (1999) Guidance for industry: population pharmacokinetics. United States Food and Drug Administration, Washington, DC
10. MR First 2008 First clinical experience with the new once-daily formulation of tacrolimus Ther Drug Monit 30 2 159 166 18367975 10.1097/FTD.0b013e318167909a 1:CAS:528:DC%2BD1cXjslSqtb4%3D (Pubitemid 351521642)
11. S Florman R Alloway M Kalayoglu K Lake T Bak A Klein G Klintmalm S Busque D Brandenhagen J Lake K Wisemandle W Fitzsimmons MR First 2005 Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen Transplant Proc 37 2 1211 1213 15848672 10.1016/j.transproceed.2004.11.086 1:CAS:528:DC%2BD2MXjsFKisbk%3D (Pubitemid 40590839)
12. FC Grenier J Luczkiw M Bergmann S Lunetta M Morrison D Blonski K Shoemaker M Kobayashi 1991 A whole blood FK 506 assay for the IMx analyzer Transplant Proc 23 6 2748 2749 1721264 1:CAS:528:DyaK38XnsFGrtQ%3D%3D
13. V Haufroid M Mourad V Van Kerckhove J Wawrzyniak M De Meyer DC Eddour J Malaise D Lison JP Squifflet P Wallemacq 2004 The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 3 147 154 15167702 10.1097/00008571-200403000-00002 1:CAS:528:DC%2BD2cXjt1Kjsrs%3D (Pubitemid 38373108)
14. DA Hesselink T van Gelder RH van Schaik 2005 The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression Pharmacogenomics 6 4 323 337 16004552 10.1517/14622416.6.4.323 1:CAS:528:DC%2BD2MXmvVaqsbs%3D (Pubitemid 40916357)
15. S Hoffmeyer O Burk O von Richter HP Arnold J Brockmoller A Johne I Cascorbi T Gerloff I Roots M Eichelbaum U Brinkmann 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 7 3473 3478 10716719 10.1073/pnas.050585397 1:CAS:528:DC%2BD3cXitlWqtL8%3D (Pubitemid 30183327)
16. DW Holt VW Armstrong A Griesmacher RG Morris KL Napoli LM Shaw 2002 International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring Ther Drug Monit 24 1 59 67 11805724 10.1097/00007691-200202000-00011 1:CAS:528:DC%2BD38XhsVOitL8%3D (Pubitemid 34106733)
17. S Irtan F Saint-Marcoux A Rousseau D Zhang V Leroy P Marquet E Jacqz-Aigrain 2007 Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients Ther Drug Monit 29 1 96 102 17304156 10.1097/FTD.0b013e3180310f9d 1:CAS:528:DC%2BD2sXhslCmtbc%3D (Pubitemid 46279882)
18. WJ Jusko 1995 Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring Ther Drug Monit 17 6 596 601 8588227 10.1097/00007691-199512000- 00009 1:CAS:528:DyaK28XltlGisA%3D%3D
19. WJ Jusko W Piekoszewski GB Klintmalm MS Shaefer MF Hebert AA Piergies CC Lee P Schechter QA Mekki 1995 Pharmacokinetics of tacrolimus in liver transplant patients Clin Pharmacol Ther 57 3 281 290 7535213 10.1016/0009-9236(95)90153-1 1:STN:280:DyaK2M3ht1SrtA%3D%3D
20. RP Kershner WE Fitzsimmons 1996 Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation Transplantation 62 7 920 926 8878385 10.1097/00007890-199610150-00009 1:CAS:528:DyaK28XmvFKrsLg%3D (Pubitemid 26360352)
21. Y Le Meur M Buchler A Thierry S Caillard F Villemain S Lavaud I Etienne PF Westeel B Hurault de Ligny L Rostaing E Thervet JC Szelag JP Rerolle A Rousseau G Touchard P Marquet N Djebli A Rousseau G Hoizey JP Rerolle O Toupance Y Le Meur P Marquet 2007 Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation Am J Transplant 7 11 2496 2503 17908276 10.1111/j.1600-6143. 2007.01983.x 1:CAS:528:DC%2BD2sXhtlakt73N (Pubitemid 47566324)
22. IA MacPhee S Fredericks T Tai P Syrris ND Carter A Johnston L Goldberg DW Holt 2004 The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 6 914 919 15147425 10.1111/j.1600-6143.2004.00435.x 1:CAS:528:DC%2BD2cXls1Sgurc%3D (Pubitemid 38745590)
23. SI Min SY Kim SH Ahn SK Min SH Kim YS Kim KC Moon JM Oh SJ Kim J Ha 2010 CYP3A5*1 Allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients Transplantation 90 12 1394 1400 21076384 10.1097/TP.0b013e3181fa93a4 1:CAS:528:DC%2BC3cXhsFGrtrvL
24. M Mourad P Wallemacq M De Meyer D Brandt V Van Kerkhove J Malaise D Chaib Eddour D Lison V Haufroid 2006 The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function Clin Chem Lab Med 44 10 1192 1198 17032130 10.1515/CCLM.2006.229 1:CAS:528:DC%2BD28XhtFyms7zF (Pubitemid 44580800)
25. RR Press BA Ploeger J Den Hartigh T Van der Straaten J Van Pelt M Danhof JW De Fijter HJ Guchelaar 2009 Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients Ther Drug Monit 31 2 187 197 19258929 10.1097/FTD.0b013e31819c3d6d 1:CAS:528:DC%2BD1MXjsFWqsbg%3D
26. JH Proost 1995 Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting Int J Clin Pharmacol Ther 33 10 531 536 8574501 1:STN:280:DyaK287itFKquw%3D%3D
27. L Quteineh C Verstuyft V Furlan A Durrbach A Letierce S Ferlicot AM Taburet B Charpentier L Becquemont 2008 Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients Basic Clin Pharmacol Toxicol 103 6 546 552 19067682 10.1111/j.1742-7843.2008.00327.x 1:CAS:528:DC%2BD1cXhsFSnsbrL
28. WJ Sam M Aw SH Quak SM Lim BG Charles SY Chan PC Ho 2000 Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients Br J Clin Pharmacol 50 6 531 541 11136292 10.1046/j.1365-2125.2000.00288.x 1:CAS:528:DC%2BD3MXkvVyqsQ%3D%3D (Pubitemid 32010014)
29. WJ Sam LS Tham MJ Holmes M Aw SH Quak KH Lee SG Lim K Prabhakaran SY Chan PC Ho 2006 Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients Clin Pharmacokinet 45 1 59 75 16430311 10.2165/00003088-200645010-00004 1:CAS:528:DC%2BD28Xis1ejsbc%3D (Pubitemid 43145015)
30. LB Sheiner SL Beal 1981 Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 4 503 512 7310648 10.1007/BF01060893 1:STN:280:DyaL38%2FnslGruw%3D%3D
31. C Staatz P Taylor S Tett 2001 Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation Nephrol Dial Transplant 16 9 1905 1909 11522877 10.1093/ndt/16.9.1905 1:CAS:528: DC%2BD3MXns1yrtb4%3D (Pubitemid 32821425)
32. CE Staatz C Willis PJ Taylor SE Tett 2002 Population pharmacokinetics of tacrolimus in adult kidney transplant recipients Clin Pharmacol Ther 72 6 660 669 12496747 10.1067/mcp.2002.129304 1:CAS:528:DC%2BD3sXltF2quw%3D%3D (Pubitemid 36021005)
33. CE Staatz C Willis PJ Taylor SV Lynch SE Tett 2003 Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation Liver Transpl 9 2 130 137 12548506 10.1053/jlts.2003.50023 (Pubitemid 36204563)
34. H Sun EO Fadiran CD Jones L Lesko SM Huang K Higgins C Hu S Machado S Maldonado R Williams M Hossain EI Ette 1999 Population pharmacokinetics. A regulatory perspective Clin Pharmacokinet 37 1 41 58 10451782 10.2165/00003088-199937010-00003 1:STN:280:DyaK1MzotFSruw%3D%3D (Pubitemid 29366759)
35. R Venkataramanan A Swaminathan T Prasad A Jain S Zuckerman V Warty J McMichael J Lever G Burckart T Starzl 1995 Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 29 6 404 430 8787947 10.2165/00003088-199529060- 00003 1:CAS:528:DyaK28XosFWntA%3D%3D (Pubitemid 26004179)
36. P Wallemacq VW Armstrong M Brunet V Haufroid DW Holt A Johnston D Kuypers Y Le Meur P Marquet M Oellerich E Thervet B Toenshoff N Undre LT Weber IS Westley M Mourad 2009 Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference Ther Drug Monit 31 2 139 152 19177031 10.1097/FTD.0b013e318198d092 1:CAS:528: DC%2BD1MXjsFWqsb0%3D
37. M Yasuhara T Hashida M Toraguchi Y Hashimoto M Kimura K Inui R Hori Y Inomata K Tanaka Y Yamaoka 1995 Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations Transplant Proc 27 1 1108 1110 7533356 1:STN:280:DyaK2M7osVequw%3D%3D
38. H Zahir AJ McLachlan A Nelson G McCaughan M Gleeson F Akhlaghi 2005 Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients Ther Drug Monit 27 4 422 430 16044097 10.1097/01.ftd.0000170029.36573.a0 1:CAS:528:DC%2BD2MXmsV2ju7o%3D (Pubitemid 41098815)
39. X Zhang ZH Liu JM Zheng ZH Chen Z Tang JS Chen LS Li 2005 Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation Clin Transplant 19 5 638 643 16146556 10.1111/j.1399-0012.2005.00370.x (Pubitemid 41341696)